Health Technology Assessment

This OHE publication is intended to inform and stimulate debate about the way different sorts of evidence and considerations are taken into account in decisions about new health care technologies. The authors argue for greater use of multiple criteria decision analysis (MCDA) as an aid to decision-making that is based on health technology assessment.

Spending by Spain’s National Health Service (NHS) on pharmaceuticals was €12.1 billion in 2010. Its market for prescription medicines is among the slowest growing in Europe, expanding by only 1% for the 12 months to September 2010 - half of the average of 2% for the five largest European markets.

OHE was awarded a UK Department of Health grant to further develop three aspects of health status indexes. Results of the second of these, advances in Time Trade Off methodology, are reported in this post.

Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For new drugs, this would replace the current PPRS system. The implications for pricing and reimbursement, and innovation, are outlined by Prof Towse in this blog post.

Members of the OHE team participated in a number of sessions at ISPOR’s 13th Annual European Congress in November. This post summarizes the contributions of Prof Nancy Devlin, OHE’s Director of Research.

The OHE recently published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by the Federal German Ministry of Health (Bundesgesundheitsministerium). The main findings of the Australian study are outlined in this post.

The OHE has just published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by the Federal German Ministry of Health (Bundesgesundheitsministerium). The main findings of the UK study are outlined in this post.

Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE's Dr Mestre-Ferrandiz reported on OHE research that examines the impact of these measures as well as whether and how pricing and reimbursement policies affect access in practice.

Earlier this month, the first set of data on post operative patient reported outcomes (PROMs) was published by the Department of Health (DH). For the first time, this has provided a patient-based assessment of changes in patients’ health related quality of life following hip replacement. The data also cover surgery on knees, varicose veins and groin hernias.

Obesity is an increasing challenge in England, as elsewhere. OHE has completed a study that examines PCT practice and the cost savings that could accrue if NICE guidance was followed more closely.

Pages

Subscribe to RSS - Health Technology Assessment